Nomura Cuts HENGRUI PHARMA TP to HKD82.18, Lowers FY2026 Revenue and Profit Forecasts
Hengrui Pharma Wins First China Approval for Home-Grown Long-Acting Insulin Analog
Hengrui Wins NMPA Nod to Move Cervical Cancer Combo to First-Line Use
Hengrui Pharma wins China approval for camrelizumab-famitinib combo as 1L cervical cancer treatment
As weight-loss drug orders surge, global funds pile into China’s WuXi AppTec
WuXi AppTec joins FTSE4Good Index Series for fourth straight year